AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Om

Telehelseplatform som tilbyr personlige helse- og velværeløsninger for menn og kvinner, inkludert dermatologi, psykisk helse, seksuell helse og vektstyringsbehandlinger.

Small cap-vekstaksjer

Hims & Hers er en raskt voksende telehelseplatform som tilbyr personaliserte wellness-løsninger for hårtap, hudpleie, seksuell helse og mental helse gjennom en direkte-til-konsument-modell.

Key Financials HIMS

Pris $16.30
Endring (1D) +3.16%
Endring (30D) -49.80%
Endring (60D) -54.19%
Endring (90D) -70.23%
Endring (180D) -69.44%
Endring (1Y) -64.83%
Endring (5Y) -30.64%
P/E-forhold 20.63
EPS (TTM) $0.79
52-ukers rekkevidde $15.63 — $72.98
50-dagers MA $31.23
Volum 26.12M

Data updated Feb 15 · Source: Twelve Data

2.8
1 reviews
Valuation
3.2
Fundamentals
3
Management Quality
2.8
Performance
2.2
Risk Profile
2
Claude Opus 4.6
AI Review
2.8/5

Hims & Hers Health operates a telehealth platform offering personalized health and wellness products, primarily in men's and women's health categories including hair loss, sexual health, and skincare. The company has demonstrated strong revenue growth and achieved profitability, with a TTM EPS of $0.79 and a now-reasonable P/E of 20.63 following a dramatic selloff.

The stock has experienced a devastating decline of over 70% from its 52-week high of $72.98, largely driven by regulatory concerns around compounded GLP-1 medications (semaglutide) and FDA actions that threaten a significant revenue stream. Trading well below its 50-day moving average of $31.23, the technical picture is deeply bearish.

Bull case: The core telehealth platform remains viable with a loyal subscriber base, the valuation is now compelling for a growth company, and management has diversified product offerings. Bear case: GLP-1 regulatory headwinds could materially impact revenue projections, competitive pressures from traditional healthcare providers are intensifying, and the stock may need time to find a floor. The elevated volume suggests ongoing institutional repositioning. This is a high-risk, potentially high-reward situation best suited for investors with strong conviction and patience.

Valuation
3.2
Fundamentals
3
Management Quality
2.8
Performance
2.2
Risk Profile
2
Feb 15, 2026
Hims & Hers Health Screenshot

Added: Feb 15, 2026

forhims.com

Latest from Otrai